Press releases

BioArctic’s patent for its product candidate antibody BAN0805, for Parkinson’s disease, is now granted in Europe

October 13, 2017

Stockholm, Sweden, October 13, 2017 – BioArctic AB (publ) (Nasdaq Stockholm:BIOA B) today announced that the European Patent Office (EPO) has decided to grant a European ...

Trading in BioArctic’s B-shares commences today on Nasdaq Stockholm

October 12, 2017

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...

BioArctic AB publishes prospectus for initial public offering on Nasdaq Stockholm

September 29, 2017

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...

BioArctic AB intends to list on Nasdaq Stockholm

September 13, 2017

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...

BioArctic enters into Collaboration with AbbVie for Parkinson’s Disease Research

September 20, 2016

BioArctic announced that it entered into a strategically important collaboration with AbbVie (NYSE: ABBV), a global biopharmaceutical company, to develop and commercialize BioArctic’s portfolio of antibodies ...

Pharmaceutical study starts in Sweden with BAN2401 in early Alzheimer patients

May 12, 2014

BioArctic Neuroscience AB today announced that the first patient in Sweden has been treated with BAN2401 in a clinical study aimed at patients with an early ...

BioArctic Neuroscience and Elos Medtech start collaboration on new treatment for spinal cord injuries

October 19, 2010

The Swedish biotech company BioArctic Neuroscience and the medtech company Elos Medtech have today signed a cooperation agreement for a new treatment of spinal cord injuries.

Drug Candidate Receives Orphan Drug Designation

April 22, 2010

The text below is a translation of a Swedish press release. BioArctic Neuroscience develops treatments to help victims of spinal cord injury. The European Medicines Agency ...

BioArctic Neuroscience and Swenora Biotech Enter Into Exclusive Licensing Agreement

June 26, 2008

Today the Swedish biotech companies BioArctic Neuroscience and Swenora Biotech have entered into an exclusive licensing agreement for a novel treatment of Spinal Cord Injury Treatment. ...